Compare AMGN & GE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMGN | GE |
|---|---|---|
| Founded | 1980 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Consumer Electronics/Appliances |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.6B | 296.4B |
| IPO Year | 2002 | 2008 |
| Metric | AMGN | GE |
|---|---|---|
| Price | $437.81 | $310.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 34 | 23 |
| Target Price | ★ $435.77 | $378.43 |
| AVG Volume (30 Days) | 2.1M | ★ 4.4M |
| Earning Date | 11-03-2026 | 10-20-2026 |
| Dividend Yield | ★ 2.30% | 0.59% |
| EPS Growth | ★ 88.23 | 35.89 |
| EPS | ★ 14.79 | 6.27 |
| Revenue | $25,424,000,000.00 | ★ $45,855,000,000.00 |
| Revenue This Year | $7.45 | $10.96 |
| Revenue Next Year | $4.54 | $11.69 |
| P/E Ratio | ★ $29.67 | $50.85 |
| Revenue Growth | 8.83 | ★ 18.48 |
| 52 Week Low | $312.39 | $268.91 |
| 52 Week High | $483.99 | $388.84 |
| Indicator | AMGN | GE |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 43.82 |
| Support Level | $338.02 | $304.80 |
| Resistance Level | $446.42 | $316.77 |
| Average True Range (ATR) | 11.75 | 10.43 |
| MACD | -4.96 | -1.19 |
| Stochastic Oscillator | 4.16 | 2.65 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; General Electric became a storied conglomerate, with peak revenue of $130 billion in 2000, until it spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.